Cargando…

Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma

BACKGROUND: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver carcinoma with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) components. We examined the clinicopathological characteristics and recurrence patterns of cHCC-CCA. Because of the rarity of cHCC-CCA,...

Descripción completa

Detalles Bibliográficos
Autores principales: Ishii, Takamichi, Ito, Takashi, Sumiyoshi, Shinji, Ogiso, Satoshi, Fukumitsu, Ken, Seo, Satoru, Taura, Kojiro, Uemoto, Shinji
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718660/
https://www.ncbi.nlm.nih.gov/pubmed/33276780
http://dx.doi.org/10.1186/s12957-020-02099-w
_version_ 1783619534075199488
author Ishii, Takamichi
Ito, Takashi
Sumiyoshi, Shinji
Ogiso, Satoshi
Fukumitsu, Ken
Seo, Satoru
Taura, Kojiro
Uemoto, Shinji
author_facet Ishii, Takamichi
Ito, Takashi
Sumiyoshi, Shinji
Ogiso, Satoshi
Fukumitsu, Ken
Seo, Satoru
Taura, Kojiro
Uemoto, Shinji
author_sort Ishii, Takamichi
collection PubMed
description BACKGROUND: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver carcinoma with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) components. We examined the clinicopathological characteristics and recurrence patterns of cHCC-CCA. Because of the rarity of cHCC-CCA, its etiology, clinicopathological features, and prognosis in comparison with other primary liver carcinoma remain unknown. Its recurrence pattern and sites in particular also need to be elucidated. METHODS: All patients who underwent hepatectomy for primary liver malignancies between 2005 and 2015 were retrospectively included in this study. RESULTS: Eight hundred and ninety-four hepatectomies were performed. Nineteen cases of cHCC-CCA (2.1%) in 16 patients were enrolled. Three patients underwent re-hepatectomy. The background of hepatitis viruses and tumor marker patterns of cHCC-CCA were similar to those of HCC and dissimilar to those of intrahepatic CCA (iCCA). Biliary invasion was common in cHCC-CCA and iCCA. The 5-year overall survival values of the cHCC-CCA, HCC, and iCCA patients were 44.7%, 56.6%, and 38.5%, respectively. The 5-year recurrence-free survival values of the cHCC-CCA, HCC, and iCCA patients were 12.2%, 28.7%, and 32.9%, respectively. The liver was the most common recurrence site. Unlike HCC, however, the lymph node was the second-most common recurrence site in both cHCC-CCA and iCCA. Pathological samples of the recurrent lesions were obtained in six patients, and four had cHCC-CCA recurrence pathologically. CONCLUSION: cHCC-CCA had a mixture of characteristics of HCC and iCCA. Many cases of cHCC-CCA remained cHCC-CCA pathologically even after recurrence.
format Online
Article
Text
id pubmed-7718660
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-77186602020-12-07 Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma Ishii, Takamichi Ito, Takashi Sumiyoshi, Shinji Ogiso, Satoshi Fukumitsu, Ken Seo, Satoru Taura, Kojiro Uemoto, Shinji World J Surg Oncol Research BACKGROUND: Combined hepatocellular-cholangiocarcinoma (cHCC-CCA) is a primary liver carcinoma with both hepatocellular carcinoma (HCC) and cholangiocarcinoma (CCA) components. We examined the clinicopathological characteristics and recurrence patterns of cHCC-CCA. Because of the rarity of cHCC-CCA, its etiology, clinicopathological features, and prognosis in comparison with other primary liver carcinoma remain unknown. Its recurrence pattern and sites in particular also need to be elucidated. METHODS: All patients who underwent hepatectomy for primary liver malignancies between 2005 and 2015 were retrospectively included in this study. RESULTS: Eight hundred and ninety-four hepatectomies were performed. Nineteen cases of cHCC-CCA (2.1%) in 16 patients were enrolled. Three patients underwent re-hepatectomy. The background of hepatitis viruses and tumor marker patterns of cHCC-CCA were similar to those of HCC and dissimilar to those of intrahepatic CCA (iCCA). Biliary invasion was common in cHCC-CCA and iCCA. The 5-year overall survival values of the cHCC-CCA, HCC, and iCCA patients were 44.7%, 56.6%, and 38.5%, respectively. The 5-year recurrence-free survival values of the cHCC-CCA, HCC, and iCCA patients were 12.2%, 28.7%, and 32.9%, respectively. The liver was the most common recurrence site. Unlike HCC, however, the lymph node was the second-most common recurrence site in both cHCC-CCA and iCCA. Pathological samples of the recurrent lesions were obtained in six patients, and four had cHCC-CCA recurrence pathologically. CONCLUSION: cHCC-CCA had a mixture of characteristics of HCC and iCCA. Many cases of cHCC-CCA remained cHCC-CCA pathologically even after recurrence. BioMed Central 2020-12-04 /pmc/articles/PMC7718660/ /pubmed/33276780 http://dx.doi.org/10.1186/s12957-020-02099-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Ishii, Takamichi
Ito, Takashi
Sumiyoshi, Shinji
Ogiso, Satoshi
Fukumitsu, Ken
Seo, Satoru
Taura, Kojiro
Uemoto, Shinji
Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
title Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
title_full Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
title_fullStr Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
title_full_unstemmed Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
title_short Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
title_sort clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7718660/
https://www.ncbi.nlm.nih.gov/pubmed/33276780
http://dx.doi.org/10.1186/s12957-020-02099-w
work_keys_str_mv AT ishiitakamichi clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma
AT itotakashi clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma
AT sumiyoshishinji clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma
AT ogisosatoshi clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma
AT fukumitsuken clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma
AT seosatoru clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma
AT taurakojiro clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma
AT uemotoshinji clinicopathologicalfeaturesandrecurrencepatternsofcombinedhepatocellularcholangiocarcinoma